#Viekira Pak

The antiviral drug, which for some people can be a beneficial adjunct to the new crop of hep C medications, has gotten a bad rap.

Part 2 of Connie Welch's interview with a hep C patient sharing her experience with hepatitis C treatment.

Hep C patient Denise shares her story about being cured with cured using Viekira Pak

FDA warns of risk of hepatitis B virus reactivation in patients coinfected with hepatitis C virus and hepatitis B virus.

This Hep story shows the power of never giving up, and the transformation that comes as a result.

The standard treatment duration is 12 or 24 weeks.

It's a year since I took my last lot of tablets. A whole year.

AbbVie has applied for approval from the FDA for a new formulation of Viekira Pak that only needs to be taken once a day

The FDA has required AbbVie to add warnings to two of its HCV treatments after receiving reports of serious liver damage.

The evening dose of AbbVie’s hepatitis C treatment Viekira Pak may interact harmfully with HIV protease inhibitors.

AbbVie has applied for new indication for Viekira Pak: to treat those with genotype 1b of virus and compensated cirrhosis without ribavirin.

Individuals taking the newest HCV treatments are often at risk of clinically significant drug-drug interactions with other medications.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.